Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | SLC16A1 | P53985 | 7/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3833867 | 0.92 | ALDH1A1 (0.39) | ALDH1A1KDM4ESLC16A1CYP3A4CYP2C9 | |
| SCHEMBL3827762 | 0.87 | SLC16A1 (0.49) | SLC16A1CYP3A4CYP2C9ABCB11 | |
| SCHEMBL3829619 | 0.84 | ADORA2B (0.45) | ALDH1A1KDM4ESLC16A1CYP3A4CYP2C9 | |
| SCHEMBL3831679 | 0.82 | SLC16A1 (0.45) | ALDH1A1KDM4ESLC16A1CYP3A4CYP2C9 | |
| SCHEMBL14845839 | 0.79 | SLC16A1 (0.50) | SLC16A1CYP3A4CYP2C9ABCB11 | |
| SCHEMBL3831618 | 0.78 | CYP2C9 (0.63) | ALDH1A1KDM4ESLC16A1CYP3A4CYP2C9 | |
| SCHEMBL3833119 | 0.78 | KDM4E (0.36) | ALDH1A1KDM4ESLC16A1CYP3A4CYP2C9 | |
| SCHEMBL3830266 | 0.77 | CYP2C9 (0.42) | KDM4ESLC16A1CYP3A4CYP2C9MAPK1 | |
| SCHEMBL10292857 | 0.77 | SLC16A1 (0.49) | SLC16A1CYP3A4CYP2C9ABCB11 | |
| SCHEMBL3826401 | 0.75 | ADORA2B (0.44) | ALDH1A1KDM4ESLC16A1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1414825-B9 | THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE | ASTRAZENECA AB (SE) | 2009-09-16 | — | — | EP | disclosed |
| US-20080207642-A1 | Thienopyrimidinediones and Their Use in the Modulation of Autoimmune Disease | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-7384950-B2 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2008-06-10 | — | — | US | disclosed |
| EP-1414825-B1 | THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE | ASTRAZENECA AB (SE) | 2007-09-26 | — | — | EP | disclosed |
| US-20040254198-A1 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254198-A1 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | TPMT, CBR1, CYP2D6 | ALDH1A1 84/4885KDM4E 1355/4885SLC16A1 3284/4885 |
| US-20080207642-A1 | Thienopyrimidinediones and Their Use in the Modulation of Autoimmune Disease | C5, TPMT, C9 | ALDH1A1 242/4885KDM4E 2081/4885SLC16A1 3369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.